Patent · US Active

Compositions and methods for cancer imaging and radiotherapy

US11712486B2 · kind B2 · utility

0Cited by
4References
9Claims
0Family size

Assignees

Inventors

Key dates

Filing dateJan 30, 2018
Grant dateAug 1, 2023
Priority date
Expiry dateJan 30, 2038

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K14/705
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention relates to a conjugated compound comprising a marker M pharmaceutically acceptable, and a peptide or pseudo-peptide P having at most 30 amino acid residues and able to bind the Low-Density Lipoprotein Receptor (LDLR) and to its use in a method of labelling and/or detecting and/or treating cancerous cells in a subject by administration of the conjugated compound to the subject an analysis of the presence and/or the amount of marker.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.